Generalized Myasthenia Gravis (gMG)Phase 1KY2024-853NCT06759948
An Early Exploratory Clinical Study of GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis
A Phase 1 study testing GC012F injection in people with Generalized Myasthenia Gravis (gMG), run by Chongbo Zhao at 1 site in China.
Trial summary
This is a single-arm, open-label and early exploratory clinical study, with the purpose to study the safety, tolerability and initial clinical efficacy of GC012F Injection in the treatment of refractory GMG and to evaluate the PK, PD characteristics and immunogenicity in subjects with refractory GMG infused with… Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Generalized Myasthenia Gravis (gMG)
- What is being tested?
- GC012F injection
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 18 participants
- Where
- 1 siteChina
- Study dates
- 15 Feb 2025to 10 Sep 2027
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Subjects who meet all the following criteria can be included in this study:
- Subjects or their legal representative voluntary signing the ICF, and willing and able to follow the procedure in this study.
- Aged between 18 and 75 years old (including 75), no gender limitation;
- Patients with confirmed refractory GMG, and the clinical classification according to MGFA is IIa-IVb (including IIa, IIb, IIIa, IIIb, IVa and IVb) at screening;
- At screening, the MG-ADL score must be ≥6, with ocular symptoms accounting for less than 50% of the total score, and QMG must be ≥11;
- Ineffectiveness of conventional treatment and/or lack of effective therapeutic options, referring to relapse or exacerbation after standard treatments with hormones, immunosuppressants (e.g., azathioprine, mycophenolate mofetil, tacrolimus, cyclosporine A, cyclophosphamide, methotrexate, etc.), or biological agents (e.g., rituximab);
Show all 19Show fewer
- If the subject is currently using corticosteroids, the dose of prednisone must not exceed 30 mg/day (or the equivalent dose of other corticosteroids) and must remain stable for at least 4 weeks prior to infusion;
- Only subjects with positive MG-specific autoantibodies: the titer/level of anti-acetylcholine receptor (anti-AChR) antibodies or muscle-specific kinase (anti-MuSK) antibodies must be above the reference laboratory's upper normal limit (UNL);
- The results of laboratory test during screening period shall meet all following criteria:
- Neu ≥1.0 × 109/L; Hb ≥8.0 g/dL; PLT ≥50 × 109/L;
- ALT ≤3 × ULN; AST ≤3 × ULN; TBIL <2 × ULN (DBIL ≤1.5 × ULN for subjects with Gilbert's syndrome)
- Creatinine clearance (19.3 Appendix 3) ≥30 mL/min;
- APTT ≤1.5 × ULN, PT ≤1.5 × ULN;
- LVEF ≥50% based on echocardiography, no findings of pericardial effusion.
- Women of childbearing potential (WCBP) should:
- Have a negative serum β human chorionic gonadotropin (β-hCG) pregnancy test confirmed by investigators during the screening period;
- Agree to avoid breastfeeding during the study period until at least 1 year after the infusion of GC012F Injection or until two consecutive flow cytometry tests show the absence of CAR-T cells (whichever occurs later).
- Any male subjects who have sexual partners and female subjects with childbearing potential shall agree to take effective contraceptive methods (e.g. oral contraceptive pills, intrauterine device or condoms) from the screening starting until at least 1 year post GC012F Injection infusion or until two consecutive flow cytometry tests show the absence of CAR-T cells (whichever occurs later). Male subjects must agree to use condoms during sexual contact with pregnant females or females with fertility for at least 1 year after the infusion of GC012F Injection, even if a successful vasectomy has been performed;
- Venous access available for blood collection, and no contraindications for leukapheresis.
Who cannot join
- Subjects who meet any of the following criteria will be excluded from the study:
- Subjects have a history of severe hypersensitivity or allergy;
- Any contraindication for fludarabine, cyclophosphamide and any component of the investigational product;
- Administration of intravenous immunoglobulin or plasmapheresis or immunoadsorption treatment within 4 weeks prior to infusion;
- Use of B-cell targeting drugs, including but not limited to rituximab, Belimumab, and Telitacicept, within 6 months prior to apheresis;
- Used tacrolimus, cyclosporine, azathioprine, mycophenolate, mycophenolate, methotrexate, etc., within 3 weeks prior to apheresis;
Show all 32Show fewer
- Treatment with neonatal Fc receptor (FcRn) antagonists (such as Efgartigimod, etc.) within 3 weeks prior to apheresis
- Use of complement inhibition therapy (such as eculizumab, etc.) within 3 weeks prior to apheresis;
- Subjects with any of the following heart diseases:
- Congestive heart failure (New York Heart Association (NYHA) Class III or IV);
- Experienced unstable angina, myocardial infarction or underwent coronary artery bypass grafting (CABG) within 6 months prior to screening period;
- Clinically significant ventricular arrhythmias or a history of unexplained syncope not due to vasovagal reaction or dehydration; or a QTc interval >480 ms during screening;
- History of severe non-ischemic cardiomyopathy.
- Serious cardiovascular abnormalities (such as abnormal brain natriuretic peptide BNP/ troponin and other indicators) and the investigators estimate that the patients should not be enrolled;
- Accompanied by other uncontrolled malignant tumors. Subjects with the following conditions will be eligible: early-stage tumors that have received curative treatment (carcinoma in situ or stage I tumors, or non-ulcerated primary melanoma with a depth <1 mm and no involvement of lymph nodes), basal cell skin cancer, skin squamous cell carcinoma, cervical carcinoma in situ, or breast cancer in situ that has received potential curative treatment;
- Severe underlying medical conditions, such as:
- Fungal, bacterial, viral or other infections or suspected fungal, bacterial, viral or other infections that cannot be controlled or require general intravenous administration (including tuberculosis infection where with clear evidence of disease activity);
- Significant clinical evidence of dementia or mental status changes;
- History of any central nervous system (CNS) or neurodegenerative diseases, (e.g., epilepsy, seizures, paralysis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, psychiatric disorders).
- Positive results in any of the following tests:
- HIV antibody positive;
- HBsAg positive; or HBcAb positive and HBV-DNA above the lower limit of detection of the analytical method;
- HCV antibody positive with HCV RNA above the lower limit of detection of the analysis method; or known history of hepatitis C without completion of antiviral therapy for ≥24 weeks;
- Syphilis antibody positive.
- Received prior therapy of CAR-T for any target;
- Previous organ transplant or allogeneic bone marrow transplants;
- Surgery within 2 weeks prior to lymphodepletion or planning to have surgery during the study period (except for planned local anesthesia procedures, provided they are not performed within 2 weeks after infusion);
- Receipt of a live-attenuated vaccine within 4 weeks prior to lymphodepletion;
- Participation in any other clinical trial within 4 weeks prior to signing ICF, or the date of signing the ICF still within 5 half-lives of the drug from the last dose in the last clinical trial (whichever is longer);
- Pregnant women or lactating women who do not agree to abstain from breastfeeding, men and women who have a fertility plan during participation in this study or within 1 year after receiving study treatment;
- Based on the Columbia-Suicide Severity Rating Scale (C-SSRS), subjects had a current intention to commit suicide, i.e., C-SSRS item 4 on "suicide" (intention to act, But active suicidal ideation without a specific plan) or question 5 (active suicidal ideation with a specific plan and intent) answered "yes" or had a current history of suicidal behavior
- Any situation that, in the investigator's judgment, may interfere with the subject's participation in the entire trial, confound trial results, or be contrary to the subject's best interests
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site
Huashan Hospital, affiliated to Fudan University, Shanghai,
Shanghai, Shanghai Municipality
Jie Song, 183 1708 6762, sdsj1990@163.com
sdsj1990@163.com
About this study
This is a single-arm, open-label and early exploratory clinical study, with the purpose to study the safety, tolerability and initial clinical efficacy of GC012F Injection in the treatment of refractory GMG and to evaluate the PK, PD characteristics and immunogenicity in subjects with refractory GMG infused with GC012F Injection.
Read the detailed description
This is a single-arm, open-label and early exploratory clinical study, with the purpose to study the safety, tolerability and initial clinical efficacy of GC012F Injection in the treatment of refractory GMG and to evaluate the PK, PD characteristics and immunogenicity in subjects with refractory GMG infused with GC012F Injection.
This study includes periods of screening, apheresis, baseline, lymphodepletion pretreatment, assessment before infusion, infusion of CAR-T cells, and Safety and efficacy follow-ups, long-term follow-ups, and withdrawal of study visits (if any).
Eligible subjects will receive the apheresis and then infusion after the production of CAR-T product. Subjects will receive lymphodepletion pretreatment, and assessments prior to CAR-T cell infusion. Subjects who meet the cell infusion criteria will receive CAR-T cell infusion with the doses specified in the protocol, and the doses in the same group or subsequent group can be adjusted based on the safety and clinical efficacy.
There're 3 dose groups in this study for CAR-T cell infusion: 1×10^5/kg, 2×10^5/kg, 3×10^5/kg. Dose will be escalated based on "3+3" rule. 3~6 subjects will be enrolled into each dose group, approximately 9~18 subjects in total will be enrolled. Subjects of each dose group will be observed for DLT within 28 days (Dose-limiting toxicities (DLT) observation period) after GC012F injection infusion.
After all proposed subjects in each dose group complete the 28-day DLT observation period, the Safety Monitoring Committee (SMC) will evaluate the clinical safety and pharmacokinetic data (if available). Only after obtaining the approval of SMC and collaborator may new subjects be enrolled in the next dose group. Additionally, in order to ensure the safety of CAR-T therapy, the SMC may recommend increasing the frequency of safety committee evaluations according to the safety situation and study progress (e.g., conducting an SMC assessment for each newly enrolled subject).
The dose escalation rules are as follows: Each dose level will enroll 3 to 6 subjects, and only after all subjects in a dose group complete the DLT assessment, meet escalation criteria, and have undergone evaluation by the SMC (considering clinical safety and pharmacokinetic data, if available) and received collaborator approval will they proceed to the next dose level.
The criteria for dose escalation are: if none of the first 3 patients in a group experience DLT during the observation period, the study may proceed to the next dose group. If one patient among the first three experiences DLT during the observation period, three additional patients will be enrolled to the same dose group. If DLT cases are ≤1 out of the total 6 enrolled patients during the DLT observation period, the study can proceed to the next dose group. If the number of DLT cases exceeds 1, dose escalation will be halted (see the table below for details) Number of DLT cases Measures 0/3 Escalation to the next dose group 1/3 Enrolled 3 additional subjects 1/6 Escalation to the next dose group
≥2/3 or ≥2/6 1. Dose escalation will be halted 2. Dose de-escalation to a lower dose level:
- If only 3 subjects were enrolled at the dose level, 3 additional subjects will be enrolled at that dose level;
- If there have been 6 subjects at the dose level, DLT cases are ≤1, the dose is MTD.
After all subjects in a dose group have completed the DLT observation period, all clinical study data collected during that period, particularly safety data, will be assessed. Following evaluation and approval by the SMC, which will consider the clinical safety and pharmacokinetic data (if available), the collaborator will decide whether to enroll new subjects in that dose group, halt or continue dose escalation, or introduce an intermediate dose group.
If more than one DLT is observed in the 1×10^5/kg dose group, following approval by the SMC, the researchers and collaborators will discuss whether to explore a lower dose group. If no DLT is observed after escalating to 3×10^5/kg, the decision to explore a higher dose group will be based on a comprehensive review of safety data, CAR-T cell expansion persistence parameters, and efficacy data, after SMC evaluation and approval, followed by discussions between researchers and collaborators.
Given that the activity of cell-based therapies (which are long-lasting) does not show a clear dose dependency, exposure of subjects to excessively low doses may not yield clinical benefit. Therefore, this study will determine or adjust the infusion dose for patients based on the safety of the GC012F injection, parameters for CAR-T cell expansion persistence, and clinical efficacy, following assessment and agreement by the SMC along with further discussions with the researchers and collaborators.
DLT assessments will be performed for evaluable subjects within 28 days post-GC012F injection. Subjects will be replaced if any of the following situations occur during the DLT assessment period: (1) subjects withdraw from the study for reasons not related to DLT, (2) prohibited medications were used prior to DLT occurrence, or (3) safety evaluations required for DLT assessment are not completed.
Following CAR-T cell infusion, subjects will be monitored for safety, cell proliferation persistence, and efficacy, until disease progression, withdrawal from the study with refusal of further follow-up, death, withdrawal of informed consent, loss to follow-up, or 24 weeks post-infusion(whichever occurs first).
- Conditions
- Generalized Myasthenia Gravis (gMG)
- Being tested
- GC012F injection
- Medical subject headings
- Myasthenia Gravis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
GC012F injectionDrug
Subjects will be infused with GC012F Injection within 48-72 hours after lymphodepletion pretreatment, the infusion dose (CAR-T cells) and groups are as follows:
- Dose group 1: 1 × 10^5/kg;
- Dose group 2: 2 × 10^5/kg;
- Dose group 3: 3 × 10^5/kg; Note: For subjects weighing ≤70 kg: number of infused CAR-T cells = (1, 2 or 3) (±20%) × 10^5 × body weight(kg); for subjects weighing >70 kg: number of infused CAR-T cells (fixed doses of GC012F Injection) = (1, 2 or 3) (±20%) × 10^5 × 70 kg.
| Study group | Role | What they receive |
|---|---|---|
| There're 3 dose groups in this study.Dose will be escalated based on "3+3" rule. | Experimental | There're 3 dose groups in this study for CAR-T cell infusion: 1×10^5/kg, 2×10^5/kg, 3×10^5/kg. Dose will be escalated based on "3+3" rule. 3~6 subjects will be enrolled into each dose group, approximately 9~18 subjects in total will be enrolled. Subjects of each dose group will be observed for DLT within 28 days (Dose-limiting toxicities (DLT) observation period) after GC012F injection infusion. Receives: Drug: GC012F injection |
What is being measured
The primary outcome is the main question the study is designed to answer.
Primary endpoints
1、DLT incidence;
DLT is defined as any of the following conditions associated with GC012F Injection occurring within 28 days post cell infusion:
- Neurotoxicity: Grade 3 and 4, which cannot recover to Grade 2 or lower within 7 days after therapeutic intervention;
- CRS: Grade 4, which cannot recover to Grade 2 or lower within 3 days after therapeutic intervention;
- Non-hematological toxicity: Grade 3 and Grade 4, involving heart, lung and kidney, which cannot recover to Grade 2 or lower within 28 days after therapeutic intervention; Grade 5;
- Hematological toxicity: Grade 4, which cannot recover to Grade 2 or lower within 3 days after therapeutic intervention. The predictable complication for chemotherapeutics is not included as a DLT in this study.
Measured: Since signing the ICF until 24-week post-infusion or premature withdrawal from the study, whichever comes first.
Primary endpoints
Abnormal results of physical examination, vital signs, laboratory tests, electrocardiography and echocardiography, and the frequency and severity of AEs.
The grading criteria for adverse event severity were based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0
Measured: Since signing the ICF until 24-week post-infusion or premature withdrawal from the study, whichever comes first.
Secondary outcomes (3)
Secondary endpoints
Disease activity index in 24 weeks after infusion including but not limited to:
- The improvement and proportion of subjects on MG-ADL score and QMG score from baseline to 24 weeks post-infusion; MG-ADL total score of 24 points. The higher the score, the more serious the impact of the disease on daily life.
- The improvement and proportion of subjects on MGC from baseline to 24 weeks post-infusion; MGC total score of 50 points. The higher the score, the more serious the impact of the life
- The mean change of PRO (including MG-QoL15r scores) from baseline to 24 weeks post-infusion; The higher the score, the more serious the impact of the life
- The change of MGFA post-intervention status from baseline to 24 weeks post infusion;
- The decrease of titer of pathogenic antibody levels and proportion of subjects from baseline to 24 weeks post-infusion;
Measured: Since signing the ICF until 24-week post-infusion or premature withdrawal from the study, whichever comes first.
Secondary endpoints
PK parameters of CAR-T cells in peripheral blood (i.e. Cmax, Tmac, AUC, etc.)
- GC012F CAR gene copy number in peripheral blood on D-1,D4,D7,D10,D14,D28,D56,D84,D168,D168+84D,D672+84D,OR withdraw
- GC012F CAR-T cell count in peripheral blood on D-1,D4,D7,D10,D14,D28,D56,D84,D168,D168+84D,D672+84D,OR withdraw
- Anti-GC012F antibody in peripheral blood on D-1,D28,D56,D84,D168,D168+84D,D672+84D,OR withdraw
- Lymphocyte subpopulations in peripheral blood and B cell related tests
- Tissue or bone marrow (if required) cell cluster related tests
- Tissue or bone marrow (if required) CAR-T gene-related tests 4.5.6 are on D-1,D7,D14,D28,D56,D84,D168,D168+84D,D672+84D,OR withdraw
- sBCMA in peripheral blood on D-1,D7,D14,D28,D56,D84,D168,D168+84D,D672+84D,OR withdraw
- RCL and Lentivirus insertion siteon D-1 M1/3/6/12/18/24, twice a year for 3-5 years and once a year for 6-15 years
Measured: Since signing the ICF until Long-term follow-up period or withdraw
Secondary endpoints
Levels of cytokine in peripheral blood [IL-2, IL-6, IL8,IL-10, IL-15, IL-17, IFN-γ, TNF-α, MCP-1and GM-CSF (if applicable), lymphocyte subsets and free BCMA in peripheral blood after GC012F infusion;
Measured: Since signing the ICF until 24-week post-infusion or premature withdrawal from the study, whichever comes first.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Jan 2025
- Study start15 Feb 2025 (estimated)
- Primary completion13 Feb 2027 (estimated)
- Study completion10 Sep 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Generalized Myasthenia Gravis (gMG)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Sequential
- Masking
- None (open label)
- Enrolment
- 18 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Chongbo Zhao
- Sponsor type
- University, hospital or other
- Collaborators
- Gracell Biotechnologies (Shanghai) Co., Ltd.
- Responsible party
- Sponsor-investigator, Chongbo Zhao, Huashan Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06759948
- Sponsor's protocol ID
- KY2024-853
- Acronym
- KY2024-853
- Status last verified
- Dec 2024
- First submitted
- 19 Dec 2024
- Last updated
- 6 Jan 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Undecided
Study at a glance
From the registry record, last updated by the sponsor on 6 Jan 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Early Exploratory Clinical Study of GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis
- ClinicalTrials.gov ID
- NCT06759948
- Acronym / sponsor ID
- KY2024-853 / KY2024-853
- Conditions
- Generalized Myasthenia Gravis (gMG)
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 18 participants (estimated)
- Lead sponsor
- Chongbo ZhaoUniversity, hospital or other
- Collaborators
- Gracell Biotechnologies (Shanghai) Co., Ltd.
- Study start
- 15 Feb 2025 (estimated)
- Primary completion
- 13 Feb 2027 (estimated)
- Study completion
- 10 Sep 2027 (estimated)
- First posted
- 6 Jan 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a single-arm, open-label and early exploratory clinical study, with the purpose to study the safety, tolerability and initial clinical efficacy of GC012F Injection in the treatment of refractory GMG and to evaluate the PK, PD characteristics and immunogenicity in subjects with refractory GMG infused with GC012F Injection.
Detailed description
This is a single-arm, open-label and early exploratory clinical study, with the purpose to study the safety, tolerability and initial clinical efficacy of GC012F Injection in the treatment of refractory GMG and to evaluate the PK, PD characteristics and immunogenicity in subjects with refractory GMG infused with GC012F Injection.
This study includes periods of screening, apheresis, baseline, lymphodepletion pretreatment, assessment before infusion, infusion of CAR-T cells, and Safety and efficacy follow-ups, long-term follow-ups, and withdrawal of study visits (if any).
Eligible subjects will receive the apheresis and then infusion after the production of CAR-T product. Subjects will receive lymphodepletion pretreatment, and assessments prior to CAR-T cell infusion. Subjects who meet the cell infusion criteria will receive CAR-T cell infusion with the doses specified in the protocol, and the doses in the same group or subsequent group can be adjusted based on the safety and clinical efficacy.
There're 3 dose groups in this study for CAR-T cell infusion: 1×10^5/kg, 2×10^5/kg, 3×10^5/kg. Dose will be escalated based on "3+3" rule. 3~6 subjects will be enrolled into each dose group, approximately 9~18 subjects in total will be enrolled. Subjects of each dose group will be observed for DLT within 28 days (Dose-limiting toxicities (DLT) observation period) after GC012F injection infusion.
After all proposed subjects in each dose group complete the 28-day DLT observation period, the Safety Monitoring Committee (SMC) will evaluate the clinical safety and pharmacokinetic data (if available). Only after obtaining the approval of SMC and collaborator may new subjects be enrolled in the next dose group. Additionally, in order to ensure the safety of CAR-T therapy, the SMC may recommend increasing the frequency of safety committee evaluations according to the safety situation and study progress (e.g., conducting an SMC assessment for each newly enrolled subject).
The dose escalation rules are as follows: Each dose level will enroll 3 to 6 subjects, and only after all subjects in a dose group complete the DLT assessment, meet escalation criteria, and have undergone evaluation by the SMC (considering clinical safety and pharmacokinetic data, if available) and received collaborator approval will they proceed to the next dose level.
The criteria for dose escalation are: if none of the first 3 patients in a group experience DLT during the observation period, the study may proceed to the next dose group. If one patient among the first three experiences DLT during the observation period, three additional patients will be enrolled to the same dose group. If DLT cases are ≤1 out of the total 6 enrolled patients during the DLT observation period, the study can proceed to the next dose group. If the number of DLT cases exceeds 1, dose escalation will be halted (see the table below for details) Number of DLT cases Measures 0/3 Escalation to the next dose group 1/3 Enrolled 3 additional subjects 1/6 Escalation to the next dose group
≥2/3 or ≥2/6 1. Dose escalation will be halted 2. Dose de-escalation to a lower dose level:
- If only 3 subjects were enrolled at the dose level, 3 additional subjects will be enrolled at that dose level;
- If there have been 6 subjects at the dose level, DLT cases are ≤1, the dose is MTD.
After all subjects in a dose group have completed the DLT observation period, all clinical study data collected during that period, particularly safety data, will be assessed. Following evaluation and approval by the SMC, which will consider the clinical safety and pharmacokinetic data (if available), the collaborator will decide whether to enroll new subjects in that dose group, halt or continue dose escalation, or introduce an intermediate dose group.
If more than one DLT is observed in the 1×10^5/kg dose group, following approval by the SMC, the researchers and collaborators will discuss whether to explore a lower dose group. If no DLT is observed after escalating to 3×10^5/kg, the decision to explore a higher dose group will be based on a comprehensive review of safety data, CAR-T cell expansion persistence parameters, and efficacy data, after SMC evaluation and approval, followed by discussions between researchers and collaborators.
Given that the activity of cell-based therapies (which are long-lasting) does not show a clear dose dependency, exposure of subjects to excessively low doses may not yield clinical benefit. Therefore, this study will determine or adjust the infusion dose for patients based on the safety of the GC012F injection, parameters for CAR-T cell expansion persistence, and clinical efficacy, following assessment and agreement by the SMC along with further discussions with the researchers and collaborators.
DLT assessments will be performed for evaluable subjects within 28 days post-GC012F injection. Subjects will be replaced if any of the following situations occur during the DLT assessment period: (1) subjects withdraw from the study for reasons not related to DLT, (2) prohibited medications were used prior to DLT occurrence, or (3) safety evaluations required for DLT assessment are not completed.
Following CAR-T cell infusion, subjects will be monitored for safety, cell proliferation persistence, and efficacy, until disease progression, withdrawal from the study with refusal of further follow-up, death, withdrawal of informed consent, loss to follow-up, or 24 weeks post-infusion(whichever occurs first).
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Sequential
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| There're 3 dose groups in this study.Dose will be escalated based on "3+3" rule. | Experimental | Drug: GC012F injectionThere're 3 dose groups in this study for CAR-T cell infusion: 1×10^5/kg, 2×10^5/kg, 3×10^5/kg. Dose will be escalated based on "3+3" rule. 3~6 subjects will be enrolled into each dose group, approximately 9~18 subjects in total will be enrolled. Subjects of each dose group will be observed for DLT within 28 days (Dose-limiting toxicities (DLT) observation period) after GC012F injection infusion. |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (19 listed)
- Subjects who meet all the following criteria can be included in this study:
Key exclusion criteria (32 listed)
- Subjects who meet any of the following criteria will be excluded from the study:
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| GC012F injectionSubjects will be infused with GC012F Injection within 48-72 hours after lymphodepletion pretreatment, the infusion dose (CAR-T cells) and groups are as follows: 1. Dose group 1: 1 × 10^5/kg; 2. Dose group 2: 2 × 10^5/kg; 3. Dose group 3: 3 × 10^5/kg; Note: For subjects weighing ≤70 kg: number of infused CAR-T cells = (1, 2 or 3) (±20%) × 10^5 × body weight(kg); for subjects weighing >70 kg: number of infused CAR-T cells (fixed doses of GC012F Injection) = (1, 2 or 3) (±20%) × 10^5 × 70 kg. | Drug | There're 3 dose groups in this study.Dose will be escalated based on "3+3" rule. |
Primary outcome
Primary endpoints
Time frame: Since signing the ICF until 24-week post-infusion or premature withdrawal from the study, whichever comes first.
1、DLT incidence; DLT is defined as any of the following conditions associated with GC012F Injection occurring within 28 days post cell infusion: 1. Neurotoxicity: Grade 3 and 4, which cannot recover to Grade 2 or lower within 7 days after therapeutic intervention; 2. CRS: Grade 4, which cannot recover to Grade 2 or lower within 3 days after therapeutic intervention; 3. Non-hematological toxicity: Grade 3 and Grade 4, involving heart, lung and kidney, which cannot recover to Grade 2 or lower within 28 days after therapeutic intervention; Grade 5; 4. Hematological toxicity: Grade 4, which cannot recover to Grade 2 or lower within 3 days after therapeutic intervention. The predictable complication for chemotherapeutics is not included as a DLT in this study.
Primary endpoints
Time frame: Since signing the ICF until 24-week post-infusion or premature withdrawal from the study, whichever comes first.
Abnormal results of physical examination, vital signs, laboratory tests, electrocardiography and echocardiography, and the frequency and severity of AEs. The grading criteria for adverse event severity were based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0
3 secondary outcomes
Secondary endpoints
Time frame: Since signing the ICF until 24-week post-infusion or premature withdrawal from the study, whichever comes first.
Secondary endpoints
Time frame: Since signing the ICF until Long-term follow-up period or withdraw
Secondary endpoints
Time frame: Since signing the ICF until 24-week post-infusion or premature withdrawal from the study, whichever comes first.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Jan 2025.
- Individual participant dataSharing planned: No. Undecided
Related trials for Generalized Myasthenia Gravis (gMG)
Not yet recruitingEarly Phase 1
A Clinical Study to Evaluate the Safety and Efficacy of GT802 Injection in the Treatment of Refractory Generalized Myasthenia Gravis
Generalized Myasthenia Gravis (gMG)
RecruitingPhase 2
ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis (MG)
Enrolling by invitationPhase 2/3
Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis
Generalized Myasthenia Gravis, gMG
RecruitingObservational study
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
Myasthenia Gravis, MG
RecruitingPhase 3
Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)
Generalized Myasthenia Gravis, gMG
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing GC012F injection in people with Generalized Myasthenia Gravis (gMG), run by Chongbo Zhao at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 19 inclusion and 32 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 6 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jie Song, Subi (18317086762, sdsj1990@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Primary endpoints (time frame: Since signing the ICF until 24-week post-infusion or premature withdrawal from the study, whichever comes first.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Jan 2025; AzTrials last refreshed its copy on 7 Nov 2026.